NIPH Clinical Trials Search

JAPANESE
国立保健医療科学院
JRCT ID: jRCTs051190058

Registered date:08/10/2019

DCF-RT for T4b EC

Basic Information

Recruitment status Recruiting
Health condition(s) or Problem(s) studiedEsophageal cancer
Date of first enrollment01/09/2019
Target sample size20
Countries of recruitment
Study typeInterventional
Intervention(s)Chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-R)

Outcome(s)

Primary OutcomeAdverse effect
Secondary OutcomeTreatment completion rate, complete response rate, treatment response rate, overall survival, salvage surgery rate

Key inclusion & exclusion criteria

Age minimum>= 20age old
Age maximum< 80age old
GenderBoth
Include criteria1 The first occurrence of thoracic esophageal cancer for which diagnosis of squamous cell carcinoma (including adenosquamous cell carcinoma and basal cell carcinoma) was obtained by histology Example (including cases that partially affect the cervical esophagus or abdominal esophagus) 2 Thoracic esophagus cancer (cT4 esophagus cancer) with clinical involvement of the aorta or trachea without curative organ metastasis. Abdominal lymph node (No. 1, 2, 3, 7, 9) metastasis-positive cases are eligible. 3 over 20 years old and under 80 years old 4 PS (ECOG) 0-1 5 There is no prior treatment for esophageal cancer. However, endoscopic resection (pT1a, ly0, v0) obtained with curative resection is acceptable. 6 No history of radiation exposure to neck and chest 7 Main organ function is maintained 8 Patients who have obtained consent from the patient
Exclude criteria1 Chemoradiotherapy is difficult to perform due to abnormalities in major organs (brain, heart, lung, liver, kidney) 2 active double cancer (However, cases that can be cured by treatment are eligible) 3 Perforation or penetration case by primary lesions or lymph nodes 4 Cases with a history of serious drug hypersensitivity 5 pregnant women, lactating women and women with the possibility and intention of pregnancy 6 Cases with severe pulmonary emphysema or pulmonary fibrosis or interstitial pneumonia recognized by lung function test, CT 7 HBs antigen positive cases 8 Cases deemed inappropriate by the investigator

Related Information

Contact

Public contact
Name Takashi Kanemura
Address 3-1-69 Otemae, Chuo-ku, Osaka-shi, Osaka,541-8567 Japan Osaka Japan 541-8567
Telephone +81-6-6945-1181
E-mail takashi.kanemura@oici.jp
Affiliation Osaka International Cancer Institute
Scientific contact
Name Hiroshi Miyata
Address 3-1-69 Otemae, Chuo-ku, Osaka-shi, Osaka, 541-8567 Japan Osaka Japan 541-8567
Telephone +81-6-6945-1181
E-mail hiroshi.miyata@oici.jp
Affiliation Osaka International Cancer Institute